Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Supernus Pharmaceuticals (GB:0LB2)
LSE:0LB2
RESEARCH TOOLSreports
Supernus Pharmaceuticals (0LB2) Share Price & Analysis
0 Followers
0LB2 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.54 - $37.48
Previous Close$29.46
Volume9.00
Average Volume (3M)93.00
Market Cap
$1.61B
Enterprise Value$1.44B
Total Cash (Recent Filing)$200.19M
Total Debt (Recent Filing)$33.84M
Price to Earnings (P/E)N/A
Beta0.89
Next Earnings
May 07, 2024EPS Estimate
$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,734,956
10 Day Avg. Volume15
30 Day Avg. Volume93
Standard Deviation0.13
R-Squared0.18
Alpha0.00401
Financial Highlights & Ratios
Price to Book (P/B)10.45
Price to Sales (P/S)2.43
Price to Cash Flow (P/CF)11.20
P/FCF Ratio11.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit2.49
Enterprise Value/Ebitda12.70
Forecast
1Y Price Target
$40.50Price Target Upside37.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Supernus Pharmaceuticals News
PremiumPress Releases
Supernus Provides Regulatory Update for SPN-830
PremiumCompany Announcements
Supernus Pharmaceuticals Enhances Executive Compensation Packages
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.52% Other Institutional Investors
96.48% Public Companies and
Individual Investors
0LB2 FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest share price was $22.54 and its highest was $37.48 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Currently, no data Available
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is May 07, 2024 which is in 13 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Feb 27, 2024. The company reported $0.883 earnings per share for the quarter, beating the consensus estimate of $0.553 by $0.33.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals does not currently pay dividends.
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is $0.26.
How many shares outstanding does Supernus Pharmaceuticals have?
Currently, no data Available
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.883 in its last earnings report, beating expectations of $0.553. Following the earnings report the stock price went down -0.08%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Among the largest hedge funds holding Supernus Pharmaceuticals’s share is Third Avenue Management LLC. It holds Supernus Pharmaceuticals’s shares valued at 5M.
---
Supernus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.50 (37.47% Upside)
$40.50 (37.47% Upside)
Blogger Sentiment
Bullish
GB:0LB2 Sentiment 75%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.01%
12-Months-Change
Fundamentals
Return on Equity
0.15%
Trailing 12-Months
Asset Growth
-23.32%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
---
0LB2 Earnings Call
Q4 2024
0:00 / 0:00
---
0LB2 Stock 12 Months Forecast
Average Price Target
$40.50
▲(37.47% Upside)
Technical Analysis
Supernus Pharmaceuticals
―
ACADIA Pharmaceuticals
―
Avadel Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Best Analysts Covering 0LB2
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+4.07%
reiterated a buy rating 10 days ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.07% per trade.
---